Insider Selling: Avantor, Inc. (NYSE:AVTR) EVP Sells 3,758 Shares of Stock

Avantor, Inc. (NYSE:AVTR - Get Free Report) EVP James Bramwell sold 3,758 shares of Avantor stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $17.53, for a total value of $65,877.74. Following the completion of the transaction, the executive vice president now directly owns 87,379 shares in the company, valued at approximately $1,531,753.87. This represents a 4.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Avantor Price Performance

Avantor stock traded down $0.34 during midday trading on Tuesday, hitting $15.54. 5,270,823 shares of the company's stock were exchanged, compared to its average volume of 5,791,369. The company has a market cap of $10.58 billion, a P/E ratio of 14.96, a PEG ratio of 1.55 and a beta of 1.28. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.70 and a current ratio of 1.07. The stock has a 50-day moving average price of $20.41 and a two-hundred day moving average price of $22.58. Avantor, Inc. has a 52-week low of $15.37 and a 52-week high of $28.00.

Avantor (NYSE:AVTR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.26 by $0.01. Avantor had a net margin of 10.49% and a return on equity of 12.17%. During the same period last year, the business posted $0.22 earnings per share. On average, equities research analysts forecast that Avantor, Inc. will post 1.06 earnings per share for the current year.

Remove Ads

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on AVTR shares. Wells Fargo & Company lowered their price objective on Avantor from $28.00 to $25.00 and set an "overweight" rating for the company in a research report on Monday, February 10th. Barclays lowered their target price on Avantor from $26.00 to $23.00 and set an "overweight" rating for the company in a report on Monday, February 10th. Citigroup reduced their price objective on shares of Avantor from $22.00 to $18.00 and set a "neutral" rating for the company in a research report on Tuesday. Morgan Stanley dropped their target price on shares of Avantor from $27.00 to $25.00 and set an "overweight" rating on the stock in a research report on Monday, February 10th. Finally, Royal Bank of Canada cut their target price on shares of Avantor from $33.00 to $31.00 and set an "outperform" rating on the stock in a research note on Monday, February 10th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, Avantor has a consensus rating of "Moderate Buy" and a consensus price target of $25.50.

Institutional Trading of Avantor

Several institutional investors have recently added to or reduced their stakes in the business. Siemens Fonds Invest GmbH bought a new stake in shares of Avantor in the 4th quarter valued at about $426,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Avantor during the 4th quarter valued at $5,712,000. American Trust raised its stake in shares of Avantor by 4.5% during the fourth quarter. American Trust now owns 15,198 shares of the company's stock valued at $320,000 after acquiring an additional 658 shares during the last quarter. Mackenzie Financial Corp grew its position in shares of Avantor by 33.0% in the 4th quarter. Mackenzie Financial Corp now owns 43,358 shares of the company's stock worth $914,000 after buying an additional 10,764 shares during the last quarter. Finally, Forum Financial Management LP purchased a new position in Avantor during the 4th quarter valued at $417,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.